Li Wang
Nanjing Medical University
7 Papers
Li Wang is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Pyroptosis & Chemistry. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Trimetazidine attenuates dexamethasone-induced muscle atrophy via inhibiting NLRP3/GSDMD pathway-mediated pyroptosis.
Li Wang,Xin-Feng Jiao,Cheng Wu,Xiao-Qing Li,Hui-Xian Sun,Xi-Yu Shen,Kang-Zhen Zhang,Can Zhao,Li Liu,Man Wang,Yun-Ling Bu,Jia-Wen Li,Fan Xu,Chen-Lu Chang,Xiang Lu,Wei Gao +15 more
TL;DR: In this article, Trimetazidine treatment ameliorated dexamethasone-induced muscle pyroptosis and atrophy both in vivo and in vitro by activating the NLR family pyrin domain containing 3 (NLRP3).
Retinol-Binding Protein 4 Promotes Cardiac Injury After Myocardial Infarction Via Inducing Cardiomyocyte Pyroptosis Through an Interaction With NLRP3.
Kang-Zhen Zhang,Xi-Yu Shen,Man Wang,Li Wang,Hui-Xian Sun,Xiu-Zhen Li,Jing-Jing Huang,Xiao-Qing Li,Cheng Wu,Can Zhao,Jia-Li Liu,Xiang Lu,Wei Gao +12 more
TL;DR: In this paper, the authors showed that RBP4 (retinol-binding protein 4) was increased both in the myocardium of left anterior descending artery ligation-induced acute myocardial infarction (AMI) mouse model and in ischemia-hypoxia-induced cardiomyocyte injury model.
13
Serum Metrnl is associated with the presence and severity of coronary artery disease.
Zhengxia Liu,Hui-Hong Ji,Hui-Hong Ji,Min-Peng Yao,Li Wang,Yue Wang,Ping Zhou,Ying Liu,Xi-Feng Zheng,Hui-Wei He,Lian-Sheng Wang,Wei Gao,Xiang Lu +12 more
TL;DR: This first case‐control study shows significant associations of serum Metrnl with the presence and severity of CAD, suggestingmetrnl might be a new promising therapeutic target for CAD.
MiR-191 inhibit angiogenesis after acute ischemic stroke targeting VEZF1.
Kang Du,Can Zhao,Li Wang,Yue Wang,Kang-Zhen Zhang,Xi-Yu Shen,Hui-Xian Sun,Wei Gao,Xiang Lu +8 more
- 07 May 2019
TL;DR: The data reveal a novel role of miR-191 in promoting ischemic brain injury through inhibiting angiogenesis via targeting VEZF1, and miR -191 may serve as a biomarker or a therapeutic target for AIS.